CPT® Code 80285

The CPT® Code 80285 refers to a laboratory test specifically designed to monitor therapeutic drug levels of voriconazole, an antifungal medication. Voriconazole is primarily utilized in the treatment of invasive fungal infections, including candidemia and pulmonary aspergillosis, particularly in immunocompromised patients. This group includes individuals suffering from conditions such as liver failure, cancer, or those who have undergone organ transplants. In addition to these primary uses, voriconazole may also be prescribed for other serious fungal or yeast infections affecting various body systems, including the skin, stomach, bladder, and kidneys, especially in cases where patients have not responded to or cannot tolerate alternative treatments. The administration of voriconazole is not without risks; it can lead to several adverse effects, including vision problems, kidney issues, severe skin reactions, pancreatitis, muscle twitching, and bone pain, particularly with prolonged use. One of the critical aspects of managing voriconazole therapy is its significant individual variation in pharmacokinetics. This means that the drug's absorption, distribution, metabolism, and excretion can differ widely among patients, leading to a nonlinear and disproportionate increase in drug exposure with higher dosages. Therefore, therapeutic drug monitoring is essential to ensure that a patient's exposure to voriconazole remains within the therapeutic range, optimizing efficacy while minimizing the risk of toxicity. The testing process involves collecting a serum or plasma sample from the patient, which is then diluted with acetonitrile. Following this, the protein precipitate is removed through centrifugation, and a diluted portion of the resulting supernatant is analyzed using tandem mass spectrometry to obtain quantitative results. This meticulous approach ensures accurate monitoring of voriconazole levels in the patient's system, facilitating appropriate adjustments to dosing as necessary.